ArticleJournal of surgical case reports2026
The many faces of perivascular epithelioid cell tumors: case series illustrating the spectrum of a rare mesenchymal tumor.
Article in Journal of surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms composed of distinctive perivascular epithelioid cells that exhibit both melanocytic and smooth muscle differentiation on immunohistochemistry. These tumors can develop in various anatomic locations and display variable biological behavior ranging from benign to aggressive malignant disease. We present a case series of four patients diagnosed with PEComa at different anatomic sites. Histopathological analysis in all cases demonstrated characteristic epithelioid or spindle-shaped morphology, with some cases showing positive staining for melanocytic markers such as HMB-45 and Melan-A, as well as smooth muscle markers. Due to their rarity, definitive management protocols are not yet well established. Surgical resection remains the primary treatment for localized disease, while systemic therapies targeting the mammalian target of rapamycin pathway may be considered for unresectable tumors or metastatic disease. This case series underscores the heterogeneity of PEComas and highlights the importance of multidisciplinary management and long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.